Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

Stephen Pianko, Stefan Zeuzem, Wan Long Chuang, Graham Foster, Shiv Kumar Sarin, Robert Flisiak, Chuan-Mo Lee, Pietro Andreone, Teerha Piratvisuth, Samir Shah, Ajit Sood, Jacob George, Michael Gould, Piyawat Komolmit, Satawat Thongswat, Tawesak Tanwandee, Jens Rasenack, Yali Li, Mingjie Pang, Y YinGilles Feutren, Ira M Jacobson

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-alpha-2b, with approximately 200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized 3:4:4:4 to one of four open-label treatment groups: pegylated IFN (Peg-IFN)-alpha-2a 180 mug qwk or albIFN 900, 1200 or 1500 mug q4wk, plus oral ribavirin 800 mg/day, for 24 weeks. Primary efficacy endpoint was sustained virologic response (SVR; HCV RNA
Original languageEnglish
Pages (from-to)623 - 634
Number of pages12
JournalJournal of Viral Hepatitis
Volume19
Issue number9
DOIs
Publication statusPublished - 2012

Cite this

Pianko, S., Zeuzem, S., Chuang, W. L., Foster, G., Sarin, S. K., Flisiak, R., Lee, C-M., Andreone, P., Piratvisuth, T., Shah, S., Sood, A., George, J., Gould, M., Komolmit, P., Thongswat, S., Tanwandee, T., Rasenack, J., Li, Y., Pang, M., ... Jacobson, I. M. (2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Journal of Viral Hepatitis, 19(9), 623 - 634. https://doi.org/10.1111/j.1365-2893.2012.01586.x